Quick Answer
IMMUNIC, INC. reported Operating Income Loss of -$103.23 million for the year ending 2025.
- IMMUNIC, INC. showed a decrease of -5.3% in Operating Income Loss from 2024 to 2025.
- This data is from IMMUNIC, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), IMMUNIC, INC.'s Operating Income Loss has declined by 977.5%.
- Historical annual values: Fiscal year 2025: -$103.23 million | Fiscal year 2024: -$98.05 million | Fiscal year 2023: -$99.22 million | Fiscal year 2022: -$119.49 million | Fiscal year 2021: -$91.67 million | Fiscal year 2020: -$48.97 million | Fiscal year 2019: -$37.03 million | Fiscal year 2018: -$12.00 million | Fiscal year 2017: -$52.66 million | Fiscal year 2016: -$41.27 million | Fiscal year 2015: -$52.12 million | Fiscal year 2014: -$50.34 million | Fiscal year 2013: -$31.40 million | Fiscal year 2012: -$9.58 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: